Mirati Therapeutics, Inc.

Good afternoon and welcome to the Merati Therapeutics second quarter 2023 earnings call. My name is Justin and I will be the operator for today's call. All lines have been placed on mute to prevent any background noise. After the conclusion of the speaker's prepared remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one. on your telephone keypad. If you would like to withdraw your question, press the pound key. It is my pleasure to introduce Ryan Acy, Vice President of Corporate Affairs at Mirati. Ryan, you may begin the call.

Thank you, Justin, and welcome everyone to this afternoon's call. Joining me on the call today are Dr. Chuck Baum, our President and Founder, Dr. Alan Sandler, our Chief Medical Officer, Dr. Jamie Christensen, our Chief Scientific Officer, Ben Hickey, our Chief Commercial Officer, and Laurie Stelzer, our Chief Financial Officer. I'd like to inform you that certain statements we make during this call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K. and our quarterly reports on Form 10Q that are filed with the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended June 30th, 2023, and recent corporate updates. This press release and accompanying second quarter earnings slide presentation are available on the investor section of our website at marati.com. Additionally, this afternoon, we also announced the launch of a public offering. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy our securities. pursuant to a shelf registration statement filed by us with the SEC that became automatically effective upon filing. We have filed a preliminary prospectus supplement and accompanying prospectus with the SEC related to the offering. These, together with the final prospectus, can be accessed on the SEC's website or the investor page of our website at maradi.com. Before we proceed, I'd like to address an important leadership transition within our organization. This afternoon, we announced the departure of David Meek and the appointment of Dr. Chuck Baum as interim CEO during the transition period while our board leads the search for a permanent CEO. With that, it's my pleasure to introduce Dr. Chuck Baum, the president, founder, and interim CEO of RUN.

Thank you, Ryan, and thank all of you for joining us on the call today. On this afternoon's call, I will provide initial remarks before turning the call over to Alan, Jamie, Ben, and Lori to provide key updates. I'll then provide some closing remarks before we open the line for questions. I would like to start by thanking David and acknowledging the significant role he played in leading the company. Under David's guidance the past two years, we have continued to advance our robust R&D pipeline and made a lasting impact on people living with cancer. During this period, we received the FDA approval and launched Crisati, becoming a commercial stage company. I express my and the company's gratitude for David's contributions. I have been appointed the interim CEO of the company. It is both an honor and a weighty responsibility to return to this role. As founder, president, and CEO of Mirati for 10 years, I am deeply committed to our mission. and I will work tirelessly to advance our robust pipeline while pushing the boundaries of novel science and best-in-class capabilities. As we navigate this transition, our mission remains unchanged. We will continue our relentless pursuit of scientific excellence and development of groundbreaking therapies and the improvement of patient outcomes. Our commitment to innovation and patience will remain at the core of everything we do. I am confident in the strength of our team and the wealth of experience we possess. Our focus is on building the capabilities needed to drive long-term sustainable growth of our business. We have a robust pipeline and innovative programs with one of the most productive drug discovery organizations in the industry. Our focus is on the areas of cancer with large unmet needs and where revolutionary treatments can have meaningful impact on the lives of patients. Today, we will highlight several important updates, which we believe are very meaningful for Mirati. In first line non-small cell lung cancer, Alan will share an updated data set, which provides clear and compelling support for the rapid advancement of this combination into phase three development in patients with TPS scores of greater than 50%. In our earlier stage pipeline, Jamie will summarize the promising initial clinical data for MRTX1719, which is our potential best-in-class molecule in the emerging field of MTA-cooperative PRMT5 inhibitors. In second line non-small cell lung cancer, Ben will describe how the differentiated profile of Cresati, along with the world-class commercial organization, have led to a strong initial launch and the promise of continued growth. Finally, Lori will share certain details regarding our recent announcement for a proposed public offering, along with a summary of our second quarter financial results. I am very optimistic and very excited about the future of Merati. We are well positioned to create significant value for shareholders, while also making a meaningful impact on the lives of people living with cancer. With that, I'll now turn the call over to Alan.